+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Von Willebrand Disease Treatment Market 2019-2023 - Product Image

Global Von Willebrand Disease Treatment Market 2019-2023

  • ID: 4704107
  • Report
  • November 2018
  • Region: Global
  • 115 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • Shire
  • MORE
The increasing awareness about VWD is likely to boost growth in the market. VWD will be present in the affected individual since the time of birth; however, the symptoms do not appear from childhood. Patients’ perceptions of symptoms such as frequent nosebleeds, staining and extreme bleeding during and after invasive events such as dental extractions and surgical procedures are general changing gradually. The analysts have predicted that the von Willebrand disease treatment market will register a CAGR of almost 7% by 2023.

Market Overview

Rising number of assistance programs for patients
The rising number of assistance programs for patients who need treatment of von Willebrand disease is pushing growth in the von Willebrand disease treatment market.

Cost intensive treatment

High cost of treatment is one of the major challenges for patients with VWD. As VWD is one of the very rare blood diseases, the patient pool available for carrying out clinical trials is negligible, which increases the research cost.

For the detailed list of factors that will drive and challenge the growth of the von Willebrand disease treatment market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be highly concentrated and with the presence of few companies including Baxter and CSL the competitive environment is quite intense. Factors such as the increasing awareness about VWD and the rising number of assistance programs for patients, will provide considerable growth opportunities to von Willebrand disease treatment manufactures. Baxter, CSL, Octapharma, Shire, and Grifols are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • Shire
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Desmopressin - Market size and forecast 2018-2023
  • Replacement therapy - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • Shire
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global rare disease drugs market
Exhibit 02: Segments of global rare disease drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Inheritance of VWD
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Desmopressin - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Desmopressin - Year-over-year growth 2019-2023 (%)
Exhibit 22: Replacement therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Replacement therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Reimbursement programs in North America for hemophilia and its related diseases
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Americas
Exhibit 34: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Patient assistance programs
Exhibit 43: Special drug designations
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Baxter - Vendor overview
Exhibit 51: Baxter - Business segments
Exhibit 52: Baxter - Organizational developments
Exhibit 53: Baxter - Geographic focus
Exhibit 54: Baxter - Segment focus
Exhibit 55: Baxter - Key offerings
Exhibit 56: Baxter - Key customers
Exhibit 57: CSL - Vendor overview
Exhibit 58: CSL - Business segments
Exhibit 59: CSL - Organizational developments
Exhibit 60: CSL - Geographic focus
Exhibit 61: CSL - Segment focus
Exhibit 62: CSL - Key offerings
Exhibit 63: CSL - Key customers
Exhibit 64: Grifols - Vendor overview
Exhibit 65: Grifols - Business segments
Exhibit 66: Grifols - Organizational developments
Exhibit 67: Grifols - Geographic focus
Exhibit 68: Grifols - Segment focus
Exhibit 69: Grifols - Key offerings
Exhibit 70: Grifols - Key customers
Exhibit 71: Octapharma - Vendor overview
Exhibit 72: Octapharma - Organizational developments
Exhibit 73: Octapharma - Key offerings
Exhibit 74: Octapharma - Key customers
Exhibit 75: Shire - Vendor overview
Exhibit 76: Shire - Business segments
Exhibit 77: Shire - Organizational developments
Exhibit 78: Shire - Geographic focus
Exhibit 79: Shire - Key offerings
Exhibit 80: Shire - Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • Shire
  • MORE
Global Von Willebrand Disease Treatment Market 2019-2023

The author of the report recognizes the following companies as the key players in the global von Willebrand disease treatment market: Baxter, CSL, Octapharma, Shire, and Grifols.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing awareness about VWD.”

According to the report, one of the major drivers for this market is the rising number of assistance programs for patients.

Further, the report states that one of the major factors hindering the growth of this market is the cost intensive treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • Shire
Note: Product cover images may vary from those shown
Adroll
adroll